PuriCore plc ("PuriCore" or the "Company")

Total Voting Rights and Share Capital

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 2 July 2010 - PuriCore (LSE: PURI), the water-based clean technology company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, today announces the following in conformity with the Financial Services Authority's ("FSA") Disclosure and Transparency Rule 5.6.

Following the Share Capital Consolidation, whereby shares have been consolidated to increase the nominal value of each Ordinary Share to 10 pence, the Company's New Ordinary Shares were admitted to trading on the London Stock Exchange and to listing on the Official List of the United Kingdom Listing Authority earlier today.  The Company's issued share capital as at 2 July 2010 consists of 22,731,043 New Ordinary Shares of 10 pence each with voting rights.  No shares are held in treasury.  Therefore, the total number of voting rights in the Company is 22,731,043.

The number of issued New Ordinary Shares (22,731,043) may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the FSA's Disclosure and Transparency Rules.

Enquiries:

About PuriCore

PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H1N1 and H5N1), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK.

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.